A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors

NCT03494231 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy

Conditions

Solid Tumor, Adult

Interventions

DRUG: HLX06

Sponsor

Henlix, Inc